* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download PPT - ACoP7
Survey
Document related concepts
Discovery and development of cephalosporins wikipedia , lookup
Discovery and development of neuraminidase inhibitors wikipedia , lookup
Prescription costs wikipedia , lookup
Discovery and development of direct thrombin inhibitors wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Drug interaction wikipedia , lookup
Prescription drug prices in the United States wikipedia , lookup
Discovery and development of direct Xa inhibitors wikipedia , lookup
Pharmacognosy wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Drug design wikipedia , lookup
Drug discovery wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Transcript
Model Based Development of a Direct Factor Xa Inhibitor S. Rohatagi1, T. Ozeki-Ishizuka2, Y. Nitsu2, F. Ezzet3, H. Kastrissios3, T.J. Carrothers3, S.J. Haworth1 1 – Daiichi Sankyo Pharma Development, Edison, NJ; 2 – Daiichi Sankyo, Tokyo; 3 - Pharsight Corporation, Mountain View, CA MOTIVATION MODEL SCHEMATIC Modeling and simulation (M&S) were employed to make dosage recommendations for human Phase 1 studies of CS-3030. PROJECTED COMPARISON Comparison across drugs shows favorable projected response profile for CS-3030, comparable to observed responses for comparator drugs. Commercial •anti-FXa activity within 0.5-0.8 IU/mL range (Enoxaparin) Clinical Utility Efficacy/ Safety Specific objectives were to: Phase 1/2/3 public trials • Predict human PK-PD of CS-3030 based on animal to human projections, • Characterize sources of variability or safety concerns, and • Simulate potential clinical outcomes as compared to other anticoagulants. 1.3 anti-FXa activity correlates to 50% reduction in DVT rate Biomarkers Efficacy/ Safety PT/INR of 2-3 fold (Warfarin) target PT fold increase of <1.5. Phase I Dose Biomarkers PK Clinical Utility Efficacy/ Safety •Pharmacokinetics •Allometric scaling of monkey PK •Monkey exposure-response for anti-FXa activity similar to human •Assume similar bioavailability •30% variability on each PK parameter Non-clinical BACKGROUND CS-3030 is an oral, direct Factor Xa (FXa) inhibitor in development for the management of thromboembolic diseases. Dose 0.75 F=0.09 4 8 12 80 160 8000 6000 4000 2000 10 20 ● ● ● ● PK/PD Disease models Animal/human correlations Basically integration of Knowledge 8 12 20 Time (Hr) CL = a WT0.782 ; V= b WT Parameter Monkey ka 0.75 h-1 V/F 7.6 L CL/F 0.5 L/h/kg Projected Human 0.75 h-1 151 L 18.2 L/h 4000 Cp (ng/mL) 4 0 2000 1 0 20 10 5 1.2 1.8 2 2.2 10 15 Time (hr) 20 2.4 • CrCL = 20 mL/min Enoxaparin Dose (mg/day) 10 20 40 CS3030 Dose (mg/day) However, doses of 10 – 80 mg show lower bioavailability and large intersubject variability. CS-3030 is mostly renally cleared. 50% greater F 50% lesser F The 2000 50 kg 100 kg 0 60 yr 4 0 4 0 20 8 12 20 8 12 CONCLUSIONS AND DISCUSSION BID Time (Hr) Female 80 Relationship Between Dose and Event Probability F=0.09 0 80 4 F=0.18 8 12 F=0.5 F=0.045 F=0.09 20 0 160 320 4 F=0.18 8 12 40 160 4 4 2 2 0 -2 10 20 -4 40 4 2 0 -2 -4 5 4 10 Arixtra, Hip, VTE Arixtra, Knee, VTE Arixtra, Hip/Knee, Bleeds Warfarin (INR=2.5), Hip, VTE Warfarin (INR=2.5), Knee, VTE F=0.5 20 80 20 2 80 Simulated Biomarker Profiles in Humans: Anti-Factor Xa Activity and PT F=0.045 Integration of animal data and public literature allowed human PK-PD to be projected under certain plausible assumptions and scenarios. Human projections for CS-3030 identified dosing regimens which provided similar efficacy and safety profiles to that of comparators Lovenox, Hip, VTE Lovenox, Knee, VTE Lovenox, Hip/Knee, Bleeds Warfarin (INR=2.5), Hip, VTE Warfarin (INR=2.5), Knee, VTE M&S was used to optimize the Phase 1 program to reduce uncertainty and test assumptions relating to bioavailability and variability, and further to provide a basis to: 0 0 -2 -2 -4 4 8 12 20 0 4 8 12 20 0 4 8 12 20 0 Time (Hr) F=0.045 F=0.09 0 •Models from Monkey Data: •Anti-FXa = 0.00782Cp – 0. 223 •PT = 1 + 0.466(anti-FXa activity) Therefore, • PT = 1 + 0.466( 0.00782 x Cp –0. 223 ) • Assume monkey exposure-response for antiFXa activity similar to human 4 8 12 0 20 Time (Hr) 40 4 F=0.18 8 12 F=0.5 20 80 160 2.0 1.5 2 4 6 8 10 Arixtra Dose (mg/day) Arixtra P(Hip VTE)=-0.63 – 0.99 dose P(Knee VTE)=-0.78 – 0.99 dose P(Bleed)=-0.46 + 0.42 dose 12 0 20 40 60 80 Lovenox Dose (mg/day) Lovenox P(HipVTE)=-0.63 – 0.028 dose P(KneeVTE)=-0.78 – 0.028 dose P(Bleed VTE)=-0.46 + 0.013 dose 1.0 0.5 5 10 0.0 20 2.0 1.5 1.0 0.5 0.0 0 4 8 12 20 0 Time (Hr) 4 8 12 Relative potency of CS-3030 is 3 times that of enoxaparin sodium (Lovenox®) for anti-FXa activity, suggesting doses up to 40 mg/day may provide similar efficacy and safety profiles to that of enoxaparin for doses up to 100 mg/day. 100 Projected Profile 100 0 100 -4 Comparison of clinical events was made using publicly available literature for three comparators: warfarin, enoxaparin sodium (Lovenox®) and fondaparinux sodium (Arixtra®). 60 Base=1.5 It was assumed that PK-PD relationships observed in cynomolgus monkeys apply to humans. Influences of patient demographics and laboratory values were investigated on response to CS-3030. 1.6 Assumes F = 0.09 2) 2- to 3-fold increase in PT (based on warfarin) Ranges of doses and bioavailability fractions were intended to compensate for any misspecification due to projection method or underlying assumptions. 1.4 4000 1) anti-FXa activity within 0.5-0.8 IU/mL range (based on enoxaparin) PK/PD for a range of CS-3030 doses (10 to 320 mg), regimens (single dose, once daily (QD) and twice daily (BID)), and bioavailability fractions (4.5 to 50%) were simulated. 5 Steady State 80 mg: Average PT Hip VTE Knee VTE Major Bleeds 20 40 60 80 Major Bleeds (%) What types of models 0 0 As early as possible 20 80 ● 8 12 DVT (%) 40 60 When do we start? 4 40 Human projections from animal FXa activity suggest doses up to 40 mg/day CS-3030 may provide similar efficacy (prevention of deep vein thrombosis) and safety (risk of bleeding) profiles to that of enoxaparin following hip and knees surgeries. 20 ● 160 Base=0.19 0 10 For a subject with severe renal impairment, average anti-FXa activity was approximately double that a healthy subject. This may suggest that appropriate dose adjustment may be warranted if target anti-FXa activity were to be maintained close to target values. 0 ● ● ● Think prospectively Provide the context for evaluating New Chemical Entities (NCEs) Inform key multi-faceted development decisions ◦ Product profiles vs. key competitors ◦ Treatment opportunities (mono vs. combo, doses) ◦ Special populations and covariates Communicate uncertainty in these attributes to decision makers Support informed Go/No-Go decision-making Ideally, critical development decisions should leverage relevant public and proprietary data Make model the basis of developing drugs Female 0 ● ● ● 50 kg 100 kg F=0.5 80 40 50 mg 100 mg 200 mg 400 mg 50% greater F 20 8 12 4 0 Renal impairment was expected to influence drug exposure, and therefore PD. effect was smaller for PT response than anti-FXa activity. HEM, CS-3030 QD, Steady-State 0.7 50 100 0 log(anti-FXa) What should we do? 0.6 CrCL = 20 mL/min F=0.18 F=0.09 F=0.045 2000 Models were developed for anti-FXa activity and fold-increase (i.e., multiples of the baseline value) in PT using the following criteria to determine the target dose range: 0.5 BID 4000 Predicted human pharmacokinetics (PK), biomarker responses (PD), and clinical outcomes were obtained using appropriate projection methods and PK/PD data from cynomolgus monkey, relative potency data and literature data. 0.4 60 yr log(PT) We model the drug as part of analysis. We are reactive 0.3 6000 log(anti-FXa) ● ● 0.2 50% lesser F 8000 Allometric scaling was used to predict human pharmacokinetics. What do we do now? 0.1 0 40 0 From: Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products, FDA, March 2004. Page 24. 0 Simulated PK profiles for 10, 20, 40, 80, 160 and 320 mg QD (left) and BID (below) at steady-state 320 8 If a single criterion was used, e.g. anti-FXa activity only, then a dose of 40 mg provided 50% time within the targetted range. Steady State 20 mg: Average Anti-Xa (IU/mL) F=0.5 Event Probability (%) 20 40 60 METHODS F=0.18 20 5000 0 Simulated PK and Biomarker Profiles: Special Populations Conc (ng/mL) 500 F=0.045 6 Proportions of the anti-FXa and PT profiles within the targeted range were consistently larger for BID regimens as compared to QD regimens. 0 concept to drug development has the potential to significantly improve it. FDA scientists use, and are collaborating with others in the refinement of, quantitative clinical trial modeling using simulation software to improve trial design and to predict outcomes. It is likely that more powerful approaches can be built by completing, and then building on, specific predictive modules.” Simulated PK Profiles in Humans: Allometric Scaling from Monkey Data Prothrombin time (PT) prolongation is known to be mediated by FXa inhibition; therefore, determination of PT and anti-FXa activity during preclinical development provides a basis for driving the drug development process towards selection of doses associated with target anti-FXa activity and PT/INR range. Event Probability (%) 20 40 60 Model-based drug development involves building mathematical and statistical characterizations of the time course of the disease and drug using available clinical data to design and validate the model. The relationship between drug dose, plasma concentration, biophase concentration (pharmacokinetics), and drug effect or side-effects (pharmacodynamics) is characterized, and relevant patient covariates are included in the model. Systematic application of this 3 None of the doses met the dual criteria of anti-FXa activity and PT response. Rather, target levels were achieved only partially over the dosing interval. RESULTS – PK/PD MODELING An International Normalized Ratio (INR) of 2-3 fold is generally considered a safe and effective anticoagulant range, thereby serving as a practical guide to dose selection for clinical use. 2.5 SUMMARY OF RESULTS Biomarkers In animal studies, CS-3030 is cleared largely by the kidney. It is not metabolized by CYP 450 isozymes and therefore is expected to have low potential for drugdrug interactions. Cp (ng/mL) “Opportunity: The concept of model-based drug development, in which pharmaco-statistical models of drug efficacy and safety are developed from preclinical and available clinical data, offers an important approach to improving drug development knowledge management and development decision making. 1.5 Fondaparinux Dose (mg/day) PK Model Based Drug Development – a FDA Critical Path Initiative QD regimen, VTE, Hip BID regimen, VTE, Hip QD regimen, Bleed, Hip BID regimen, Bleed, Hip Warfarin (INR=2.5), VTE, Hip Warfarin (INR=2.5), Bleed, Hip 70 = Lovenox, Arixtra and others = CS-3030 0 Modeling and simulation (M&S) was employed to recommend doses for human Phase I studies of a direct Factor Xa (FXa) inhibitor, CS-3030. Predicted human pharmacokinetics (PK), biomarker responses (PD), and clinical outcomes were obtained using appropriate projection methods and PK/PD data from cynomolgus monkey, together with literature data. Models were developed for anti-FXa activity and fold-increase in prothrombin time (PT) compared to baseline using the following criteria to determine the target dose range: (1) anti-FXa activity within 0.5-0.8 IU/mL range (based on enoxaparin) and (2) 2- to 3-fold increase in PT (based on warfarin). PK/PD for a range of CS-3030 doses (10 to 320 mg), regimens (single dose, once daily (QD) and twice daily (BID)) and bioavailability fractions (4.5 to 50%) were simulated. The ranges of doses and bioavailability fractions were intended to compensate for any misspecification due to projection method or underlying assumptions. Influences of patient demographics and laboratory values were investigated on response to CS-3030. No one dose met the dual criteria of anti-FXa activity and PT response. Rather, target levels were achieved only partially over the dosing interval. If a single criterion was used, e.g. anti-FXa activity only, then a dose of 40 mg provided 50% time within the targeted range. Renal impairment was expected to influence drug exposure, and the effect was smaller for PT response than anti-FXa activity. Appropriate dose adjustment is thus possible for different populations. Human projections from animal FXa activity suggest doses up to 40 mg/day CS-3030 may provide similar efficacy (prevention of deep vein thrombosis) and safety (risk of bleeding) profiles to that of enoxaparin doses up to 100 mg/day following hip and knees surgeries. In conclusion, M&S led to identification of key elements to be studied earlier than usual, i.e., bioavailability and the effect of renal clearance, and the FIM study could be designed accordingly. This illustrated the application of M&S to guide drug development and inform the design of clinical trials. OBJECTIVES Event Probability (%) 10 20 30 40 50 60 ABSTRACT 20 0 10 20 30 CS-3030 Dose (mg) 40 ●Estimate the likely quality of Phase 2 dose-response in Phase 1 planning. ●Quantify the effect of covariates, the magnitude and sources of uncertainty, and key assumptions. This example illustrates the application of M&S to guide drug development and inform the design of clinical trials.